Tissium S.A.

https://www.tissium.com

LinkedIn: https://www.linkedin.com/company/tissium

TISSIUM is a privately-owned medtech company based in Paris, France and Boston, USA that is dedicated to the development and commercialization of a unique biopolymer platform to address multiple unmet clinical needs, including atraumatic tissue repair and reconstruction. TISSIUM is developing a portfolio of solutions that leverage its proprietary family of fully biosynthetic, biomorphic and programmable polymers, which are the foundation of the company’s technology platform. Currently, the Company has a pipeline of seven products across three verticals, including nerve repair, hernia and cardiovascular. Each product is designed to enhance the tissue reconstruction process in a unique way. The company also develops delivery and activation devices for enhanced performance and usability of its products. TISSIUM’s technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-founded the company in 2013. *

	Start	2019-05-14 renamed
	Group	Tissium (Group)
	Predecessor	Gecko Biomedical (FR)
	Industry	tissues
	Industry 2	polymers
	Person	Bancel, Christophe (Gecko Biomedical 201603 CEO + Co-Founder)

	Region	Paris
	Country	France
	Street	74 rue du Faubourg Saint-Antoine
	City	75012 Paris
	Tel	+33-1-7621-7220
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Tissium S.A.. (8/31/21). "Press Release: Tissium Raises €50M in Series C Financing to Propel Its Platform to Commercial Stage". Paris.

		Record changed: 2024-02-12